Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Regulatory Affairs

Northern Ireland Invests £1.95m in Endometriosis Services

Sreepriya Prasannan
Sreepriya Prasannan

NewsWritten by our team from the primary sources linked below. Reviewed, verified and approved by a human editor. How we check

Speed:
Northern Ireland Invests £1.95m in Endometriosis Services

Northern Ireland's Department of Health will invest £1.95 million in endometriosis services, Health Minister Robbie Butler announced on 2 November 2026. The money gives £700,000 to the two Regional Endometriosis Centres in the Belfast and Western Trusts and £1.25 million, shared equally, to all five Health and Social Care Trusts.

The Department describes this as the Phase 1 investment. It is meant to improve access to care, cut waiting times and support a new Regional Endometriosis Pathway. The Minister made the announcement during a visit to the Regional Endometriosis Centre at Belfast City Hospital, where a Da Vinci 5 robotic surgery platform is now used for gynaecology.

Key Highlights:
  • Total: £1.95 million Phase 1 investment in endometriosis services across Northern Ireland (Department of Health, 2 November 2026).
  • Specialist centres: £700,000 for the Regional Endometriosis Centres in the Belfast and Western Health and Social Care Trusts.
  • Local services: £1.25 million distributed equally across the five Health and Social Care Trusts to support local improvements and the Regional Endometriosis Pathway.
  • Robotic surgery: 130 patients needing complex surgery have had robotic assisted surgery at Belfast City Hospital since the platform launched in May 2026.
  • Funding source: the Executive's £80 million Programme for Government funding package for elective care in 2026/27.

What does the £1.95 million pay for?

The Department's notes to editors set out two parts. The first is £700,000 for Northern Ireland's two Regional Endometriosis Centres, run by the Belfast Health and Social Care Trust and the Western Health and Social Care Trust. The second is £1.25 million "distributed equally across the five Health and Social Care Trusts". Shared equally, that works out at £250,000 for each Trust.

The Trust money is for local service improvements and for putting the new Regional Endometriosis Pathway into practice. The Department has not published how each Trust will spend its share, how many staff or clinics it will fund, or a timetable for the pathway. Those details are not disclosed.

How the Phase 1 endometriosis investment is split
ElementAmount
Regional Endometriosis Centres (Belfast and Western Trusts)£700,000
Five Health and Social Care Trusts, shared equally£1,250,000
Total Phase 1 investment£1,950,000

What did the Health Minister say?

Minister Butler said: "For too many women, endometriosis can affect every aspect of daily life. Many have experienced long waits for diagnosis and treatment while living with significant pain and uncertainty."

He added: "This £1.95 million investment is an important step towards improving access to diagnosis, treatment and support. Through investment in specialist services, local care and a regional pathway, women will receive the right care, in the right place, at the right time."

Professor Mark Taylor, Regional Clinical Director for Elective Care, said: "Endometriosis care relies on multi-disciplinary teams working across hospitals and services to provide co-ordinated care and support. Alongside advances in robotic-assisted surgery, that collaboration is helping us deliver increasingly complex treatments in less invasive ways and support faster recovery for patients."

How does robotic surgery fit in?

The Regional Endometriosis Centre at Belfast City Hospital has a dedicated Da Vinci 5 robotic surgery platform for gynaecology. According to the Department, 130 patients who needed complex surgery have had robotic assisted operations since it launched in May 2026. The capital cost of the platform was paid by Belfast Health and Social Care Trust Charitable Funds, with revenue support from the Department of Health. The purchase price was not disclosed.

What has happened to gynaecology waiting lists?

The Department linked the announcement to its wider work on gynaecology waits. It said earlier funding of £1.8 million for assessment and triage and £1.9 million for procedural nursing capacity is helping more women get gynaecology care.

The figures below are as published by the Department. It did not publish a separate waiting list count for endometriosis.

Waiting list figures quoted by the Department of Health, 2 November 2026 (the release does not say whether the outpatient totals cover gynaecology only)
MeasureFigure
Outpatient waiting lists, Northern Ireland, September 202554,770
Outpatient waiting lists, Northern Ireland, September 202647,318
Patients waiting more than one year for inpatient and day case treatmentDown 56%
Belfast Trust, women waiting for a first outpatient gynaecology appointmentDown 4%
Belfast Trust, longest wait for a first appointment2 years and 10 months
Belfast Trust, longest inpatient and day case waitDown from 7 years to 3 years

The investment also supports the Getting It Right First Time (GIRFT) Report for Gynaecology. A Regional Health and Social Care Gynaecology Services Forum has been set up to oversee service improvement across the region.

Why is diagnosis of endometriosis so slow?

The Department describes endometriosis as "a chronic condition in which tissue similar to the lining of the womb grows elsewhere in the body and can cause severe pelvic pain, fatigue and fertility problems". The World Health Organization's fact sheet of 15 October 2025 states: "Endometriosis affects an estimated 10% (190 million) of reproductive age women worldwide."

NICE guideline NG73, Endometriosis: diagnosis and management, first published in September 2017 and last updated on 11 November 2024, says "Delayed diagnosis is a significant problem for women with endometriosis" and that "Delays of 4 to 10 years can occur between first reporting symptoms and confirming the diagnosis."

How does this compare with the Republic of Ireland?

South of the border, the HSE and its National Women and Infants Health Programme run two supra-regional endometriosis centres, at Tallaght University Hospital and Cork University Maternity Hospital, backed by a network of regional hub services. When the Cork centre opened in April 2025, the HSE said the Government had invested over €5 million to fund staffing across endometriosis services since 2021. The two systems are funded and organised differently, so the figures are not directly comparable.

Frequently asked questions

How much is Northern Ireland investing in endometriosis services?

£1.95 million in Phase 1, announced by Health Minister Robbie Butler on 2 November 2026.

Which hospitals and Trusts benefit?

The Regional Endometriosis Centres in the Belfast and Western Trusts receive £700,000. All five Health and Social Care Trusts share £1.25 million equally.

Will there be a Phase 2?

The Department calls this the Phase 1 investment but has not announced the amount or timing of any further phase.

I think I may have endometriosis. What should I do?

This article is not medical advice. If you have symptoms such as severe period pain or ongoing pelvic pain, talk to your GP.

Outlook

The next steps to watch are how each Trust uses its £250,000 share, when the Regional Endometriosis Pathway is published in full, and whether the Department reports endometriosis-specific waiting times. Priya Life Science will update this report if the Department of Health or the Trusts publish further detail.

Sources

Cover image: AI-generated illustration.

Reviewed for editorial accuracy by Sreepriya Prasannan, Founder & Editor MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany
Our standards
Related from our data
Evaluation of Wellbeing and Patient Reported Outcomes After Open vs Robotic Mastectomy With DIEP Reconstructi… — Recruiting in Ireland · Trials Tracker
Drugs in this article: current clinical trials
Most-trialled drugs in our registers
Browse all trial registers →

Get the Friday brief

One email every Friday: a 60-second summary, then only the topics you choose: industry news, approvals and market access, shortages, Irish trials, careers or data, all built from public registers.

Free. Unsubscribe from any email with one click. See our privacy policy.

About the Author
Sreepriya Prasannan

Sreepriya Prasannan

Writer at Priya Life Science · Regulatory Affairs

Sreepriya Prasannan is the Founder and Editor of Priya Life Science, Ireland's independent pharma, biotech and MedTech platform. She holds an MSc in Digital Transformation (Life Science) from Griffith College Dublin, with a background in QA, GMP and production operations. Shortlisted for STEM Graduate of the Year at the Business Post Women in STEM Awards 2026 and a Top 14 finalist in the HSE Spark Ignite 2026 innovation programme, she writes on regulatory trends, GMP compliance and careers across the Irish and European life sciences.

Discussion
No comments yet. Be the first to share your thoughts!
Leave a Comment